Search research articles
Contact Us
Filters
Showing results (81-90 of 329) with videos related to
Page
of 33
Sort By:
European Journal of Pharmacology
|
August 15, 2002
Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain
Emma S J Robinson, Robin J Tyacke, David J Nutt, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 17, 2021
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence
Anne K Schlag, Chandni Hindocha, Rayyan Zafar, et al.
Elife
|
October 12, 2020
DMT alters cortical travelling waves
Andrea Alamia, Christopher Timmermann, David J Nutt, et al.
Journal of Neuroscience Methods
|
August 2, 2005
The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo
Emma S J Robinson, David J Nutt, Helen C Jackson, et al.
Addiction Biology
|
February 23, 2017
Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health
Aldo Badiani, Kent C Berridge, Markus Heilig, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 4, 2012
The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers
Innar Tõru, Eduard Maron, Mait Raag, et al.
Frontiers in Human Neuroscience
|
June 7, 2014
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
Leor Roseman, Robert Leech, Amanda Feilding, et al.
Journal of Psychopharmacology (Oxford, England)
|
May 1, 2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression
Brandon Weiss, David Erritzoe, Bruna Giribaldi, et al.
Acta Poloniae Pharmaceutica
|
April 6, 2006
Preparation, structure and affinity for imidazoline I2 receptors and alpha2-adrenoceptors of 1-[(4,5-dihydroimidazolidin-2-yl)imino]indan-2-ols
Anita Kornicka, Franciszek Saczewski, Robin J Tyacke, et al.
Journal of Psychopharmacology (Oxford, England)
|
March 15, 2006
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers
Jayne E Bailey, Adrian Kendrick, Alison Diaper, et al.
Page
of 33
Search research articles
Search
Showing results (81-90 of 329) with videos related to
Sort By:
Page
of 33
European Journal of Pharmacology
|
August 15, 2002
Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain
Emma S J Robinson, Robin J Tyacke, David J Nutt, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 17, 2021
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence
Anne K Schlag, Chandni Hindocha, Rayyan Zafar, et al.
Elife
|
October 12, 2020
DMT alters cortical travelling waves
Andrea Alamia, Christopher Timmermann, David J Nutt, et al.
Journal of Neuroscience Methods
|
August 2, 2005
The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo
Emma S J Robinson, David J Nutt, Helen C Jackson, et al.
Addiction Biology
|
February 23, 2017
Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health
Aldo Badiani, Kent C Berridge, Markus Heilig, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 4, 2012
The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers
Innar Tõru, Eduard Maron, Mait Raag, et al.
Frontiers in Human Neuroscience
|
June 7, 2014
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
Leor Roseman, Robert Leech, Amanda Feilding, et al.
Journal of Psychopharmacology (Oxford, England)
|
May 1, 2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression
Brandon Weiss, David Erritzoe, Bruna Giribaldi, et al.
Acta Poloniae Pharmaceutica
|
April 6, 2006
Preparation, structure and affinity for imidazoline I2 receptors and alpha2-adrenoceptors of 1-[(4,5-dihydroimidazolidin-2-yl)imino]indan-2-ols
Anita Kornicka, Franciszek Saczewski, Robin J Tyacke, et al.
Journal of Psychopharmacology (Oxford, England)
|
March 15, 2006
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers
Jayne E Bailey, Adrian Kendrick, Alison Diaper, et al.
Page
of 33